Core Cap Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Core Cap Advisors, LLC
- $2.12 Billion
- Q4 2024
A detailed history of Core Cap Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 35,880 shares of CPRX stock, worth $834,927. This represents 0.04% of its overall portfolio holdings.
Number of Shares
35,880
Previous 400
8870.0%
Holding current value
$834,927
Previous $7,000
10585.71%
% of portfolio
0.04%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CPRX
# of Institutions
345Shares Held
102MCall Options Held
7.7KPut Options Held
15.4K-
Black Rock Inc. New York, NY18.7MShares$435 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$196 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$135 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$72.9 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$70.1 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.39B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...